Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK

INTRODUCTION: iGlarLixi is indicated as an adjunct to diet and exercise in addition to metformin (with or without sodium-glucose cotransporter-2 inhibitors) to improve glycemic control in adults with insufficiently controlled type 2 diabetes (T2D). A cost-effectiveness analysis was conducted to comp...

Descripción completa

Detalles Bibliográficos
Autores principales: McCrimmon, Rory J., Palmer, Karen, Alsaleh, Abdul Jabbar Omar, Lew, Elisheva, Puttanna, Amar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174356/
https://www.ncbi.nlm.nih.gov/pubmed/35543869
http://dx.doi.org/10.1007/s13300-022-01267-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174356/
https://www.ncbi.nlm.nih.gov/pubmed/35543869
http://dx.doi.org/10.1007/s13300-022-01267-3

Ejemplares similares